Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza.

摘要: Influenza is an important cause of hospitalization due to lower respiratory tract involvement for which there no specific antiviral treatment with proven efficacy. We conducted a double-blind, randomized, placebo-controlled trial assess the tolerability and efficacy nebulized zanamivir (16 mg four times day) in combination rimantadine compared saline treating influenza adults hospitalized influenza. Twenty patients tolerated inhaled (ZNV) plus without decline peak expiratory flow rates 21 who received saline. The study was terminated early because approval ZNV made further enrollment untenable. No significant differences were observed proportion shedding virus by day 3 (57% rimantadine, 67% placebo rimantadine), or durations supplemental oxygen use. More recipients exhibited mild cough on (94 vs 55%, P=0.01). Two rimantadine-resistant viruses emerged during monotherapy; resistance observed. Nebulized appears be well this population but studies are needed its